Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2025
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 studyB Pistilli, K Jhaveri, S-A Im, et al.
ESMO Open|July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)D Dano, A Lardy-Cleaud, A Monneur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancerA Mamann, Y Pradat, F C Bidard, et al.
ESMO Open|July 24, 2026
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 studyH S Rugo, K Jhaveri, S Pernas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2019
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysisA R Ferreira, A Di Meglio, B Pistilli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2024
A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years laterA Di Meglio, J Havas, M Pagliuca, et al.
Nature Communications|July 2, 2025
Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slidesI Garberis, V Gaury, C Saillard, et al.
ESMO Open|July 10, 2026
Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners FoundationS Peters, M-L Meyer, F André, et al.
ESMO Open|January 20, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancerF Lynce, C Valenza, S M Niman, et al.
Pageof 3